多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸
Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
84.3分
★★★★☆
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ALL SOURCES
全部资讯 76
条件筛选 · 已选 3 项 · 共 76 条展开收起
靶点
以双特异性抗体 XmAb 18968 靶向 CD38 治疗复发/难治性急性髓系白血病和 T 细胞急性淋巴细胞白血病患者
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia
82.5分
★★★★☆
站内排序·非疗效
新诊断多发性骨髓瘤的一线治疗
First-line Therapy in Newly Diagnosed Multiple Myeloma.
79.4分
★★★★☆
站内排序·非疗效
从静态风险到动态疾病监测：MRD 与免疫图谱在多发性骨髓瘤中的作用
From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.
79.1分
★★★★☆
站内排序·非疗效
多发性骨髓瘤：2026 年诊断、风险分层与管理更新
Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management.
79.1分
★★★★☆
站内排序·非疗效
双特异性抗体作为复发/难治性多发性骨髓瘤 BCMA CAR-T 细胞治疗的桥接
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
65.9分
★★★☆☆
站内排序·非疗效
靶向 BCMA 或 GPRC5D 的双特异性抗体在 CAR-T 细胞治疗后复发多发性骨髓瘤中高度有效
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
65.5分
★★★☆☆
站内排序·非疗效
多发性骨髓瘤中的双特异性抗体与 T 细胞衔接器
Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma.
64.3分
★★★☆☆
站内排序·非疗效
ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
63.4分
★★★☆☆
站内排序·非疗效
整合免疫疗法治疗多发性骨髓瘤
Integrating Immune Therapies for the Treatment of Multiple Myeloma.
63.3分
★★★☆☆
站内排序·非疗效